EFFICACY AND SAFETY OF METHOTREXATE VERSUS ACITRETIN IN CHRONIC PLAQUE PSORIASIS
Article Sidebar
Published:
Feb 13, 2017
Keywords:
Methotrexate, Acitretin, Chronic Plaque psoriasis
Main Article Content
Abstract
Objectives: To compare the treatment efficacy and safety of methotrexate with acitretin in chronic plaque psoriasis.
Methodology: A total of 142 patients were enrolled, 71 patients in each group. Patients were randomly divided into two groups, A and B by lottery method. They were given methotrexate (25 mg injection deep I/M once weekly) or acitretin (0.4mg/kg orally daily). At the end of 24 weeks, response to treatment was evaluated in terms of reduction in PASI score. Safety of treatment was accessed in terms of laboratory investigations i.e. transaminase, triglycerides, platelets and white blood cells during treatment.
Results: In methotrexate group, an excellent response (PASI-75%) was noted in 38 (53.5%), good response (PASI-50%) in 13 (18.3%), fair response (less than 50% reduction in PASI) in 4 (5.6%), and no response was observed in 1(1.4%) patients. In acitretin treated group excellent response was noted in 18 (25.3%), good response in 27 (38.0%), fair response in 8 (11.2%), and no response was observed in 5 (7.04%) of patients.
Conclusion: Methotrexate is better option for treatment of moderate to severe plaque psoriasis than acitretin.
Methodology: A total of 142 patients were enrolled, 71 patients in each group. Patients were randomly divided into two groups, A and B by lottery method. They were given methotrexate (25 mg injection deep I/M once weekly) or acitretin (0.4mg/kg orally daily). At the end of 24 weeks, response to treatment was evaluated in terms of reduction in PASI score. Safety of treatment was accessed in terms of laboratory investigations i.e. transaminase, triglycerides, platelets and white blood cells during treatment.
Results: In methotrexate group, an excellent response (PASI-75%) was noted in 38 (53.5%), good response (PASI-50%) in 13 (18.3%), fair response (less than 50% reduction in PASI) in 4 (5.6%), and no response was observed in 1(1.4%) patients. In acitretin treated group excellent response was noted in 18 (25.3%), good response in 27 (38.0%), fair response in 8 (11.2%), and no response was observed in 5 (7.04%) of patients.
Conclusion: Methotrexate is better option for treatment of moderate to severe plaque psoriasis than acitretin.
Article Details
How to Cite
1.
Noor SM, Ayub N, Paracha MM. EFFICACY AND SAFETY OF METHOTREXATE VERSUS ACITRETIN IN CHRONIC PLAQUE PSORIASIS. J Postgrad Med Inst [Internet]. 2017 Feb. 13 [cited 2024 Dec. 25];31(1). Available from: https://jpmi.org.pk/index.php/jpmi/article/view/2031
Issue
Section
Original Article
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.